Our Commitment to Patients, Payers, and Physicians
At Alnylam, we all live by a shared philosophy when it comes to patient access: Our innovative therapies must get to those who may benefit from them. That philosophy of putting the patient first isn’t just a belief common among our leadership and employees, it’s a statement of intent and a specific set of actions that we’ve undertaken as a company. As part of our commitment, we publish an annual Patient Access Philosophy Report as a read-out on our progress.
Our Patient Access Philosophy was created well before our first medicine was even approved, because we wanted to ensure that in preparing to be a commercial-stage biopharmaceutical company, we had a north star guiding how we behave and the decisions we make to ensure that patients around the world can access every medicine we develop.
Too often, patients have trouble accessing the medicines prescribed by their doctors, and this is especially true for innovative new medicines for diseases that previously had limited or inadequate treatment options. People living with these diseases deserve no less than our very best when it comes to research and development, and they equally deserve no less than access to the latest treatments when they become available. To that end, we recognize that Alnylam has an important role to play. – John Maraganore, Ph.D., CEO of Alnylam